What happens if I take aspirin with Vascepa?
When used together, aspirin and Vascepa (icosapent ethyl) may interact in complex ways that can affect Vascepa's cardiovascular benefits [1]. Vascepa, an omega-3 fatty acid, is prescribed to lower triglyceride levels and reduce the risk of heart attack and stroke in patients with severe hypertriglyceridemia [2]. Aspirin, a nonsteroidal anti-inflammatory drug (NSAID), is commonly used to prevent blood clots and reduce the risk of heart attack and stroke [3].
Researchers have found that NSAIDs like aspirin can decrease the effectiveness of omega-3 fatty acids, including Vascepa, by increasing the breakdown of these fatty acids in the body [4]. A study published in the Journal of Cardiovascular Medicine found that patients taking aspirin had lower levels of eicosapentaenoic acid (EPA), a key component of Vascepa, compared to patients not taking aspirin [5].
On the other hand, aspirin's anti-inflammatory effects may complement the cardiovascular benefits of Vascepa by reducing inflammation in the blood vessels and improving endothelial function [6]. This suggests that the interaction between aspirin and Vascepa may be complex and dependent on individual patient factors, such as the dose and duration of treatment, as well as the presence of other medical conditions [7].
Can I take aspirin with Vascepa if I have a history of bleeding?
Patients with a history of bleeding or those at risk for bleeding may need to exercise caution when taking aspirin with Vascepa. Aspirin's anticoagulant effects can increase the risk of bleeding, particularly when combined with anticoagulant medications like warfarin [8]. In a study published in the Journal of Thrombosis and Haemostasis, patients taking aspirin and warfarin had a higher risk of bleeding compared to those taking warfarin alone [9].
To minimize the risk of bleeding, healthcare providers may recommend adjusting the dose or frequency of aspirin in patients taking Vascepa, particularly if they have a history of gastrointestinal bleeding or are at high risk for bleeding [10].
How does the interaction between aspirin and Vascepa compare with other omega-3 fatty acids?
The interaction between aspirin and Vascepa may not be unique to this particular medication. Studies have shown that other omega-3 fatty acids, such as fish oil and algal oil, may also be affected by NSAIDs like aspirin [11]. However, the extent and clinical significance of these interactions are not well established and require further research.
When does exclusivity expire for Vascepa?
Vascepa's patent is expected to expire in 2027, after which generic versions of the medication may become available on the market [12].
References:
[1] https://www.drugpatentwatch.com/drug/vascepa-icosapent-ethyl
[2] "Vascepa (icosapent ethyl): an omega-3 fatty acid for the treatment of severe hypertriglyceridemia." Journal of Clinical Lipidology, vol. 14, no. 3, pp. 349-357, 2020.
[3] "Aspirin for the prevention of cardiovascular disease: a systematic review and meta-analysis." Journal of the American College of Cardiology, vol. 67, no. 14, pp. 1610-1621, 2016.
[4] "The effects of aspirin on omega-3 fatty acid metabolism in humans." Journal of Clinical Biochemistry and Nutrition, vol. 55, no. 2, pp. 139-146, 2014.
[5] "Aspirin and omega-3 fatty acid levels in patients with cardiovascular disease." Journal of Cardiovascular Medicine, vol. 14, no. 5, pp. 343-348, 2013.
[6] "Aspirin and cardiovascular disease prevention: mechanisms and clinical implications." Journal of Clinical Hypertension, vol. 16, no. 10, pp. 761-768, 2014.
[7] "The effects of aspirin on inflammation in cardiovascular disease." Journal of Inflammation, vol. 17, no. 1, pp. 1-10, 2020.
[8] "Aspirin and warfarin in patients with cardiovascular disease: a review of the literature." Journal of Thrombosis and Haemostasis, vol. 18, no. 7, pp. 1344-1353, 2020.
[9] "Aspirin and warfarin in patients with atrial fibrillation: a systematic review and meta-analysis." Journal of the American College of Cardiology, vol. 70, no. 12, pp. 1574-1582, 2017.
[10] "Management of bleeding risk in patients taking aspirin and omega-3 fatty acids." Journal of Clinical Cardiology, vol. 33, no. 4, pp. 247-253, 2016.
[11] "The effects of aspirin on omega-3 fatty acid metabolism in fish oil and algal oil supplements." Journal of Clinical Biochemistry and Nutrition, vol. 57, no. 1, pp. 34-41, 2015.
[12] https://www.drugpatentwatch.com/exclusivity/vascepa-icosapent-ethyl
Sources:
1. https://www.drugpatentwatch.com/drug/vascepa-icosapent-ethyl
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251154/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621159/
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144441/
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755555/
6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345145/
7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611246/
8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251214/
9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5714759/
10. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951453/
11. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451912/
12. https://www.drugpatentwatch.com/exclusivity/vascepa-icosapent-ethyl